Objective: Bacillus Calmette-Guérin (BCG) 
INTRODUCTION
Carcinoma of the urinary bladder is the most common malignant tumor of the urinary tract and the second most common malignancy, after prostatic carcinoma, of the urogenital system. Males are about three times more frequently affected than females (1) . Seventy-four percent of cases are superficial at the time of diagnosis, of which 70% are stage Ta and 30% are stage T1. Low-grade non-invasive tumors may be treated with resection and fulguration. However, despite complete tumor resection, two thirds of patients will develop tumor recurrence in five years and by 15 years, 88% of patients will develop a recurrence.
Progression from superficial bladder cancer to deep muscle invasion occurs in 15% of patients. The high rate of tumor recurrence and potential progression provides an opportunity to institute chemoprevention or prophylactic therapy (2, 3) . The initial treat ment of superficial b ladder cancer (SBC) is transurethral resection of all visible bladder tumors (TURBT) fo llo wed by adjuvant intravesical immunotherapy, most commonly with Bacillus Calmette-Guerin (BCG), which is offered to patients at high risk for tumor recurrence and/or development of invasive disease (4) . BCG therapy has been shown to delay or prevent tumor recurrence, stage progression, decrease the need for subsequent cystectomy, and improve overall survival (5) . Ho wever, a significant proportion of patients do not respond to intravesical BCG therapy; their tumors persist or recur early after BCG and may become invasive and/or metastatic. Cystectomy is an effective salvage therapy for patients in whom BCG therapy fails, as it has been shown to prevent stage progression and death (6) . In that regard, a tool to predict the response to intravesical BCG therapy would be invaluable, as it could define a subset of patients that may benefit fro m early salvage cystectomy (3) . The antineoplastic effect of BCG is most likely the result of a combination of enhanced activity of various arms of the immune system. After intravesical instillation, live mycobacteria attach to the urothelial lining, facilitated by fibronectin, a component of the extracellular matrix. This process leaves bacterial cell surface glycoproteins attached to epithelial cell membranes, and this antigen is thought to mediate the immune response (7, 8) . Intravesical instillation of bacillus CalmetteGuérin (BCG) has been established as the most efficient strategy for the prophylaxis of superficial bladder cancer recurrence after complete resection of visible tumors. The antitumor effects of intravesical instillation of BCG vaccine rely mainly on its activation of local immune response, and many factors in both BCG itself and host status are related to therapeutic efficacy (9) . Fibronectin is a glycoprotein with a mo lecular weight of 440 kDa, found in soluble form in plas ma and other body fluids, and in an insoluble (matrix) form in basement membranes and the extracellular matrix. Fibronectin (FN) seems to play a key role in progression and invasion of malignant tumors (10) . BCG ce lls possess specific high-affinity receptors to fibronectin molecules (9) . The initial crucial step in BCG therapy seems to be the binding of mycobacteria to the urothelial lining which depends on the interaction of a fibronectin attachment protein (FAP) on the bacterial surface with the fibronectin in the bladder wall (10) . In vitro studies showed that a stable BCG/ fibronectin interaction was dependent on FAP binding to fibronectin (9) . In vivo studies show FAP to be a necessary protein for the stable attachment of BCG to the bladder wall (10) . Pretreat ment of BCG with soluble fibronectin competit ively blocks the binding of BCG to exposed matrix (insoluble) fibronectin; this could result in the preferential and irreversible binding of BCG to soluble fibronectin. Th is would decrease the attachment of BCG to the bladder wall and subsequently reduce its efficacy. Moreover, stable binding of BCG via FAP within the bladder was shown to be necessary for the expression of BCG-induced antitumor activ ity (11) . Despite of BCG successful use in the prevention of superficial bladder cancer recurrence, non-responders and certain side effects remain a major obstacle (12) . Established approaches for detecting bladder cancer include urine cytology and cystoscopy, used singly or in sequence (10) . However, the invasiveness and relatively high cost of cystoscopic examination and the limited sensitivity of urinary cytology, especially for low-grade superficial lesions, make it of the utmost importance to develop a non invasive, reliable, and simp le test to increase the rate of detection of superficial bladder cancer. During the last two decades, the better understanding of the molecular mechanisms involved in carcinogenesis and tumor progression has provided a large number of mo lecular markers of b ladder cancer, with a potential diagnostic and prognostic value (13) . Among the markers investigated for that purpose, an important role has been played by telomerase activity (14) . Telo merase is a ribonucleoprotein consists of three subunits: an RNA component (hTR), wh ich acts as a template for DNA replication; a telomerase-associated protein (TP1) of unknown function; and the telomerase reverse transcriptase (hTERT), which is responsible for catalytic activity (15) Exclusion criteria: Patients with previous intravesical treatment of any kind (TURBT, BCG, and biopsy) within the three months preceding the operation, massive hematuria, documented infection, significant proteinuria and finding of residual/recurrent tumor on the first follow-up cystoscopy were excluded from the study. Written consent was taken from all participants. From all patients, about 100 ml morning urine samples were collected, 1 day before and 2 days, two weeks, six weeks, three months, six months and one year after TURBT. Samples were not collected on the first day after TURBT because several patients were still connected to bladder irrigation and in some patients the bleeding remained significant. All patients included in this study were selected from Urology Departments, Tanta University Hospital, Egypt. Also, about 100 ml morning urine samples were collected from 10 healthy volunteers who served as controls (group I). Aliquots of urine samples were stored at -70ºC for the subsequent use.
Urine preparation:
From all subjects, about 100 ml morning urine samples were collected for routine urine analysis, cytological examination and specific investigations. Urine samples were directly transported on ice to the laboratory where they immediately processed. Each urine sample was divided as following; 10 ml for routine urine analysis, 5 ml for culture and sensitivity if indicated, specimen was tested with the hemoglobin dipstick, 15 ml were sent to the Pathology Department, Faculty of Medicine, Tanta University for cytological examination and 10 ml were used for estimation of fibronectin after removal of particulates by centrifugation and storing samples at -70°C until the time of the assay. For the quantitative analysis of the catalytic subunit of the complex human telomerase reverse transcriptase (hTERT) in urine, 12 ml of fresh urine were collected in 15 ml test tube and centrifuged at 2000 rpm, at 4ºC for 5 minutes immediately after collection for reduction of the denaturing effects of RNases and proteases that are present in the urine. After discarding the supernatant, the cell pellet was resuspended in 1400 µl phosphate buffer saline (PBS) (4 ºC) and transferred to 1.5 ml Eppendorf tube. The tube was centrifuged at 2000 rpm, at 4ºC for 5 minutes; the supernatant was discarded (21) . The cell pellet was stored at -70 ºC until RNA isolation.
Patients group didn't show any history of upper urinary tract disorders as confirmed by radiological and laboratory investigations. Superficial bladder cancer diagnosis was based on clinical, radiological, cystoscopy and histopathological examinations. Culture and sensitivity tests for proper antibiotic treatment were done for all bladder cancer cases that showed associated cystitis, consent was taken from all subjects included in the current study.
Serum samples:
Peripheral venous blood samples were taken and transferred to disposable tubes. The tubes were promptly centrifuged at 4ºC, and aliquots of serum were immediately stored at -70ºC for estimation of blood urea and serum creatin ine and for indirect hemagglutination test for schistosomiasis. All subjects were subjected to the following:
1 Amplification of GAPDH as an endogenous control is performed to standardize the amount of sample RNA added to a reaction, the quality of RNA and the RT-PCR assay efficiency. For each experimental sample, the amount of hTERT-mRNA and the GAPDH reference is determined fro m the appropriate standard curve. Then, the hTERTmRNA amount is divided by the GA PDH reference amount to obtain a normalized hTERT-mRNA (32) . The sequences of the primers and probe of the GAPDH control are: GAPDH forward primer: 5'-GAA GGTGAA GGTCGGA GTC-3' GAPDH reverse primer: 5'-GAA GATGGTGATGGGATTTC-3' GAPDH Probe: VIC-CAA GCTTCCCGTTCTCA GCC-TAMRA 1-Setting up the plate document with the GeneA mp 5700 SDS software and starting the PCR run. Statistics: All the statistical analyses were processed using Statistical Program of Social Sciences (SPSS) for windows, version 10.0. Values of the measured parameters were expressed as range & mean value ±SD and the difference between each two groups was determined using unpaired student's t-test for comparing patients' results with controls while paired ttest was used for comparing the results of follo w up in patients group, and the significance was considered at p values <0.001 up to <0.05. Mult iple receiver operating characteristic curves (ROC curves) were drawn to assess the validity of the tumor markers.
Analysis of the results:
Table (1) showed insignificant difference between the age and sex distribution in all studied groups (p>0.05). A ll selected patients were suffering fro m superficial bladder cancer of transitional cell carcino ma type (TCC). As regards pathological stage, pTa represented 55% (n=11), pT1 represented 40% (n=8) and Cis represented 5% (n=1). As regards pathological grade, G1 represented 65% (n=13) and G2 represented 35% (n=7).
Cytological examination of all patients revealed the presence of five positive cases, five suspicious cases and ten negative cases (negative means no atypical cells were detected, positive means the detection of cells with malignant changes, while suspicious means the presence of few suspected cells with atypical changes, suspicious cytology results scored as positive for sensitivity and specificity calculation). In control group, all ten studied reference subjects had negative cytological examination. All patients were negative for cytology, three months after management. Six months after TURBT, five patients showed positive cytological examination (three positive and two suspicious cases as regard the cytology) and tumor recurrence was confirmed h istopathologically.
Hemoglobin dipstick of all cases revealed the presence of three patients with negative hemoglobin dipstick results. In control group, five studied reference subjects had positive hemoglobin dipstick results (+). All patients were negative for hemoglobin dipstick one month after management. Three months later, five patients showed positive results with hemastix examination. All selected patients and control were negative for indirect schistosomal hemagglutination test. Blood urea level of control group ranged 27-53 mg/dl, with a mean of 42.1±4.5, while for patients group, it is ranged 36-60 mg/dl, with a mean of 47.7±7.8 with insignificant difference between both groups (P>0.05). Seru m creatinine level of control group ranged 0.7-1.3 mg/dl, with a mean of 0.98±0.11, wh ile for patients group, it is ranged 0.8-1.5 mg/d l, with a mean of 1.1±0.19 with insignificant difference between both groups (P>0.05).
In the present study it was shown that urinary fibronectin level and normalized hTERT-mRNA were significantly higher in superficial bladder cancer patients before TURBT ( There was insignificant differences in urinary fibronectin and hTERT-mRNA levels between the patients group, one year after TURBT (formed of 15 non-recurrent cases after TURBT) (1.09 ± 0.82, 0.0, respectively) and the control group (group I) (1.58± 0.39, 0.057± 0.04, respectively) (P> 0.05).
hTERT expression was detected more than 0.33 in two reference subjects of group I, while the other eight control subject were at the zero level so normalized hTERT-mRNA of group I ranged 0.0 -0.37, with a mean value of 0.057 ±0.04.
In patients group II, normalized hTERT was detected positive in 18 cases out of 20 cases ( ≥0.33), while the other two patients were at the zero level. hTERT-mRNA of group II before TURBT ranged 0.0 -9.04, with a mean value of 4.18± 0.62. The mean urinary fib ronectin level in the ten healthy volunteers was 1.58±0.391 (0-4 ng/ml). The levels of urinary fibronectin before TURBT in patients with superficial bladder TCC were used to differentiate them into two subgroups; subgroup A formed of five patients who had significantly elevated fibronectin levels (all were T1) (649.60±268.8ng/ml) if co mpared with subgroup B which is formed of the other 15 patients (12 patients were Ta, 2 patients were T1 and one patient was Cis) in who m the mean fibronectin value was 47.06±21.07 ng/ml (P<0.001) ( Figure (2) shows ROC curve of fibronectin in u rine. The cut-off value for patients group versus control subjects was >20 mg/ ml, with 90% sensitivity and 100% specificity, PPV was 100%, NPV was 90% and accuracy was 93.3%. The area under the curve was 0.765. Two patients have urinary fibronectin level below the cut-off value. All control subjects had fibronectin level less than 20 mg/ ml (the cutoff value).
Table (4) shows comparison between studied markers (cytology, Hb dipstick, fibronectin and hTERTmRNA) as regard the sensitivity, specificity, PPV%, NPV% and accuracy for diagnosis of SBC. There was insignificant relation between any of the studied markers with the age or sex in the studied groups (p> 0.05). Co mplementary usage of normalized hTERT-mRNA expression with cytology raised the specificity fro m 80% for hTERT-mRNA alone to 100% if co mbined with cytology. However, co mp lementary usage of normalized hTERT-mRNA expression with Hb dipstick raised the sensitivity fro m 85% for hTERT-mRNA alone to 90% when co mbined with Hb dipstick, while the complementary usage of normalized hTERT-mRNA with urinary fibronectin raised both the sensitivity and the specificity to 100%.
Table (5 ) shows the clinical outcome and the results of studied urine markers during the last two follow up visits before recurrence detection (three and six months after TURBT) in patients subgroup A (n=5) and it shows progressive increase in these markers with no response to BCG therapy. Follow up was done for all patients after TURBT, but the five recurrent cases were excluded fro m the one year follow up visit. Collectively, out of 20 patients, only five of them showed recurrence with a higher stage or grade within a period of 6 months, the other 15 patients showed no recurrence during the follow up period. and Ghoneim (56) who explained that finding by the fact that males are mo re exposed to environmental and occupational risk factors than females. Most of the cases of the present study were in the sixth decade of life and all cases were transitional cell carcino ma (TCC). It has been reported recently that there is an increase in the incidence of changing in the pattern of bladder cancer from squamous to transitional cell carcinoma as TCC represented 62.8%, wh ile squamous cell carcino ma (SCC) represented 26.8% of all reported cases (57) . The cause of the increased incidence of TCC even among bilharzial associated bladder cancer in the last few years may be due to the appearance of new environmental factors among Egyptian population; however this needs further studies (56, 57) . Histopathologic classification of bladder carcino mas revealed that 11 out of 20 TCC cases had superficial non-invasive tumors (Ta) and represented (55%), 8 out of 20 TCC cases had pT1 (the cancer has started to grow into the connective tissue beneath the bladder lining and represented (40%) and one case out of 20 had carcinoma in situ (CIS) and represented (5%). As regards pathological grade, G1 represented 65% (n=13) and G2 represented 35% (n=7).
Group B (n=15) ------------------------------------------------Group A (n=5)
Cytological examination of all patients revealed the presence of five positive cases, five suspicious cases and ten negative cases. In control group, all ten studied reference subjects had negative cytological examination. All patients were managed by TURBT fo llo wed by BCG vaccine instillation started from the second week after TURBT and continued for six subsequent weeks. All patients were negative for cytology six weeks after TURBT. Six months later, five cases showed positive cytological examination (three positive and two suspicious cases) where tumor recurrence was confirmed h istopathologically.
Cytological examination of the studied cases showed low sensitivity (50%) but high specificity (100%) for diagnosis of superficial bladder cancer with an accuracy 66.6%. That finding was in agreement with those of Halling et al.
(58) who reported that the low sensitivity of cytology could be contributed to the difficu lty of cytology in detecting well differentiated tumors, or the presence of few cancer cells that may be insufficient for cytological evaluation.
Hemoglobin dipstick of all cases revealed the presence of three patients with negative hemoglobin dipstick results. In control group, five studied reference subjects had positive results. All patients were negative for Hb dipstick one month after management.
Three months later, five cases showed positive or trace results with hemoglobin d ipstick. Hemoglobin screening of the studied cases by hemoglobin d ipstick test (hemastix) revealed relatively good sensitivity (85%) and lo w specificity (50%) in the diagnosis of superficial bladder cancer. Although hematuria is a common presentation of bladder cancer, it is also a common finding in other genitourinary disorders such as urinary tract infections, benign prostatic hyperplasia (BPH) and stones; this may explain the low specificity of hemastix (59) . In the present study it was found that urinary fibronectin level was significantly higher in superficial bladder cancer patients before TURBT (group II) when compared to the control group (group I). There was significant increase in urinary fibronectin in the patients group, two days after TURBT when compared to its value before TURBT. Urinary fibronectin level showed progressive significant decrease in patients group, 2 weeks, 6 weeks, three months, six months and one year (15 patients only) after TURBT when compared to patients group, two days after TURBT.
The values of urinary fibronectin of patients did not reach to the control values and remained high till the sixth months visit and the lowest level achieved only by fifteen patients (1.09 ± 0.82) who showed insignificant difference when compared to the control group (1.58± 0.39) in the one year visit (P>0.05). The remaining five patients during the sixth month follow up visit showed recurrent tumor growth, so they were excluded from the statistics in the one year follow up visit.
These results could be explained as follows; the turnover of the suburothelial matrix might be responsible for the low but measurable urinary fibronectin levels in healthy individuals. The precise explanation for increased urinary fibronectin level in the presence of TCC of the bladder, in the present study, is the effect of a tumor-derived protease which may be responsible for increasing the release of fibronectin from bladder matrix during the multistep process in tumor invasion and metastasis (60, 61) . The study demonstrated higher urinary concentration of fibronectin in patients with superficial bladder cancer than healthy subjects. Sanchez-Carbayo et al. (62) also reported a significant differences among malignant, benign and normal control groups and reported that the degenerative change or exfoliation of bladder cancer cells can cause release of fibronectin or its fragments into urine (63) , this can explain the marked differences among malignant versus control groups in the present study and in previous studies (64,65) . Peak levels of fibronectin in all patients occurred immediately after surgery and continued for 2 days. That increase represents large amounts of fibronectin leaking into the bladder during and immediately after surgery. Theoretically, a h igh level of fibronectin after surgery may o rig inate fro m three sources. The first is persistent bleeding from the resected areas, accompanied by soluble fibronectin orig inating fro m plasma (65.66) . The second is the surgical destruction of bladder basement membranes and extracellular matrix, both of which are rich in fibronectin (67) . The third is tumor tissue itself, wh ich has high fibronectin content (60) . In agreement with the current results, Laufer et al.
(68) who reported an increased urinary fibronectin levels after transurethral resection of noninvasive bladder tumors and then decreased 2 weeks after the operation but he did not follow up the patients later. The rapid increase in urinary fibronectin, two days after TURBT in the present study might be related to the surgical intervention, hematuria or the high fibronectin tumor content but hematuria cannot be regarded as the only source of fibronectin in the urine samples of our patients due to the persistent high fibronectin levels after regression of hematuria. Also, the persistence of high levels of fibronectin even after the healing of the bladder urotheliu m (two weeks later), supports the suggestion that the high fibronectin level was produced by the tumor cells.
Insoluble (matrix) fibronectin has an important role in the adherence and activity of BCG. Matrix fibronectin is found in the basement membranes and submucosa of the bladder, and is absent from the healthy luminal surface (60) . Tumor resection exposes fibronectin molecules to the bladder contents. The high-affinity receptors of BCG can react with both soluble and matrix fib ronectin, and this binding is essentially irreversib le at normal urinary pH (66) . Therefore, the presence of significant amounts of soluble fibronectin in the urine released from the tumor tissues, as noted here, could result in the preferential and irreversible binding of BCG to soluble fibronectin. Th is would decrease the attachment of BCG to the bladder wall and subsequently reduce its efficacy, so that a possible role of fibronectin in the failure of BCG therapy was concluded.
Urinary fib ronectin levels decreased significantly in the follow up visits but their levels collectively did not reach to the normal range. This could be explained by the persistent high level of urinary fibronectin in five out of twenty SBC patients which affecting the final statistics results, so patients with superficial b ladder TCC in the present study (group II) were differentiated into two subgroups according to the levels of urinary fibronectin before TURBT; group A formed of five patients who had significantly elevated fibronectin levels and did not normalized after TURBT (5 patients were T1), group B which is formed of the other 15 patients (12 patients were Ta, 2 patients were T1 and one patient was Cis) in who m the fib ronectin level was significantly lower than group A and normalized within 6 weeks after TURBT. Furthermo re, within group A there was no association between fibronectin levels before TURBT and the presence of gross hematuria or the estimated volume of the tumor. BCG immunotherapy started from the second week post TURBT and continued weekly for six subsequent weeks. Higher level of group A fibronectin was associated six months later with recurrence of carcino ma and so this high level may be related to the residual malignant tissues after TURBT which also causes resistant BCG therapy and causing failure of BCG and recurrence. There are insufficient data to suggest whether this urine marker is of value in anticipating virulent progression of cancer but proved data for affection of BCG therapy was obtained (9,10,11 ) . Subgroup B, one year after TURBT (n=15), showed insignificant difference in urinary fibronectin level (1.09 ± 0.21) when co mpared to the control group (1.58± 0.39)(p<0.001). While for subgroup A with persistent high level of urinary fib ronectin followed by recurrence of the tumor, most probably due to the high level of soluble fibronectin wh ich can co mpete efficiently with the matrix form of fibronectin for binding to the specific receptors on the mycobacteria (FAP) and could consequently dimin ish the effect of BCG and increase the possibilit ies for recurrence.
ROC curve analysis for urinary fibronectin level gave the optimu m cut-off value for patients group versus control subjects which was >20 mg/ ml, with 90% sensitivity and 100% specificity and 93.3% accuracy. The area under the curve was 0.765. All patients with superficial bladder cancer had fibronectin >20 (the cutoff value).
In the present study, hTERTmRNA was quantified by using realtime RT-PCR and it was detected in the urine of two control subjects (group I), whereas the remaining samples were below the cut-off value (cut-off value >0.33). This was in disagreement with the study of DeKok et al.
(69) who reported zero hTERT exp ressions in tissue biopsies fro m healthy bladders. This seems reasonable as telomerase activity appears to be strictly regulated during development and during embryonic differentiation in most somatic cells (70) . The positive data with detectable hTERT was restricted to two subjects out of five females with associated chronic cystitis. These results are in agreement with those of Sanchini et al.
(53) who attributed this to the presence of a higher fraction of inflammatory and non-bladder epithelial cells in wo men than in men. This is probably due to the shorter female urethra, which favors the entrance of bacteria into the bladder and which could, at least in part, explain the false positive hTERTmRNA assay results. Therefore, once the contaminating elements largely present in urine samples has been demonstrated, it will be possible to improve diagnostic accuracy in wo men by subtracting the telomerase activity belonging to non-tumor epithelial cells fro m the total hTERTmRNA. La ncelin et al.
(71) reported telomerase activity in 2 of 4 including chronic cystitis. Also, Leber et al.
attributed the hTERT expression in non malignant bladder disorders to activated lymphocytes in these inflammatory disorders.
In the present study, it was found that urinary normalized hTERT-mRNA was significantly higher in patients group before TURBT (group II) versus control group (group I). There was significant decrease in urinary hTERT-mRNA in patients subgroup B received BCG after TURBT until it reached to zero one year after TURBT. On the other hand, apoptotic cells were markedly increased in the treated cases. This could be exp lained as BCG has been documented to induce downregulation of telomerase activity in a variety of in vitro models (including bladder cancer cell lines) raising the possibility that hTERT may be a marker of response to BCG (37,38) . Also, hTERT activity has been shown to provide prognostic and predictive informat ion in a variety of epithelial neoplasms (75,76,77,78) . At the same time, patients of subgroup A, showed insignificant difference in hTERTmRNA before and after TURBT, even after BCG instillat ion and by follow up for this subgroup, there was a resistant high level of hTERT followed by recurrence six months after TURBT. Failure of BCG by high level of soluble fibronectin causing suppression of BCG down-regulation activity on telomerase resulting in upregulation of telomerase and inhibit ion of p53-induced apoptosis resulted in recurrence. These results suggest that the reduction of telomerase activity is related to the mechanis m of BCG effects. Possible mechanis ms to be considered are either that BCG inhibits telomerase first, or that it induces apoptosis and decreases telomerase activity as a result of that induction (38) . Patients with high hTERT tu mors had a worse recurrence free survival compared to patients with low hTERT tumors. Baseline higher pre-BCG expression of hTERT was associated with subsequent development of invasive disease after BCG. A lso, the persistent rise of telo merase may be considered as indicator of the future resistance of the tumor to BCG therapy or increase the possibility of recurrence.
The present study showed 85% sensitivity and 80% specificity, for hTERT expression in the diagnosis of superficial b ladder cancer. De-Kok et al.
(69) , also reported high specificity for hTERT but in bladder biopsies fro m d ifferent non-neoplastic bladder disorders using real t ime PCR. Bowles et al.
(79) reported a specificity of 93.5% for hTERT exp ression in urinary sediments from d ifferent non neoplastic bladder diseases using mu ltip lex hTERT/ GA PDH RT-PCR. Previous studies have reported several candidate predictive factors of response to adjuvant BCG but a practical marker with good independent predictive value has not been identified (80) . In that regard, traditional pathological tu mor characteristics (81) , mo lecular markers such as p53
(82) and immunological markers such as purified protein derivative skin reaction (PPD) (83) do not appear to have a consistent predictive value. Expression of hTERT wou ld be a good predictor of BCG response for three reasons. Firstly, BCG has been documented to induce down-regulation of telomerase activity in a variety of in vitro models, raising the possibility that telomerase may be a marker of response to BCG (37,38) . Secondly, in the case of hTERT, the association between nucleolar telomerase activity and hTERT mRNA exp ression has been well documented and validated (84,85) . Thirdly, hTERT activity has been shown to provide prognostic and predictive information in a variety of epithelial neoplasms including gastric, renal, hepatocellu lar, lung and colon cancers 
CONCLUSION
The assessment of fibronectin and hTERT-mRNA in urine represents a highly sensitive tool for early detection of SBC.
It seems conceivable that these emerging urinebased tests may progressively replace urine cytology and form a reliable adjunct to cystoscopy in the diagnosis of bladder cancer. Both urinary fibronectin and hTERT mRNA in addition to being both of them fro m the best markers for diagnosing bladder carcino ma, can be used to determine the presence of residual tumor load after TURBT of bladder TCC. These parameters also can be used for follow up of patients with superficial b ladder cancer after TURBT and to predict the sensitivity of a tumor to BCG instillat ion before therapy. They could be used as predictors for selecting the appropriate patients for BCG t reat ment.
